{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Daily+dosing&page=8",
    "query": {
      "intervention": "Daily dosing",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 3690,
    "total_pages": 369,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Daily+dosing&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Daily+dosing&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T05:20:59.362Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02562898",
      "title": "Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Pancreatic Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Margaret Tempero",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2015-10-12",
      "completion_date": "2020-09-01",
      "has_results": true,
      "last_update_posted_date": "2021-05-06",
      "last_synced_at": "2026-10-27T05:20:59.362Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Portland, Oregon",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02562898"
    },
    {
      "nct_id": "NCT00715559",
      "title": "Cysteamine Therapy for Major Depressive Disorder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "cysteamine bitartrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 3,
      "start_date": "2008-07",
      "completion_date": "2009-05",
      "has_results": true,
      "last_update_posted_date": "2017-04-07",
      "last_synced_at": "2026-10-27T05:20:59.362Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00715559"
    },
    {
      "nct_id": "NCT01934361",
      "title": "Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "buparlisib",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "lomustine",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2014-02-28",
      "completion_date": "2016-07-07",
      "has_results": false,
      "last_update_posted_date": "2020-12-09",
      "last_synced_at": "2026-10-27T05:20:59.362Z",
      "location_count": 5,
      "location_summary": "Phoenix, Arizona • Fayetteville, Arkansas • Chicago, Illinois + 2 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01934361"
    },
    {
      "nct_id": "NCT01445769",
      "title": "Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Myelofibrosis",
        "Post-Polycythemia Vera Myelofibrosis",
        "Post-Essential Thrombocythemia Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2011-09",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2019-03-27",
      "last_synced_at": "2026-10-27T05:20:59.362Z",
      "location_count": 21,
      "location_summary": "Highland, California • La Jolla, California • Los Angeles, California + 18 more",
      "locations": [
        {
          "city": "Highland",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01445769"
    },
    {
      "nct_id": "NCT03690154",
      "title": "A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancer",
        "Solid Tumors",
        "Acute Myeloid Leukemia Refractory",
        "Acute Myeloid Leukemia, in Relapse"
      ],
      "interventions": [
        {
          "name": "FN-1501",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2018-07-23",
      "completion_date": "2022-02-11",
      "has_results": false,
      "last_update_posted_date": "2023-10-13",
      "last_synced_at": "2026-10-27T05:20:59.362Z",
      "location_count": 2,
      "location_summary": "Fairway, Kansas • Detroit, Michigan",
      "locations": [
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03690154"
    },
    {
      "nct_id": "NCT00996866",
      "title": "Vitamin D Supplementation Requirement in Obese Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Vitamin D Deficiency"
      ],
      "interventions": [
        {
          "name": "Vitamin D3",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Winthrop University Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 27,
      "start_date": "2008-12",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2023-07-03",
      "last_synced_at": "2026-10-27T05:20:59.362Z",
      "location_count": 1,
      "location_summary": "Mineola, New York",
      "locations": [
        {
          "city": "Mineola",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00996866"
    },
    {
      "nct_id": "NCT05017545",
      "title": "Carfilzomib and Belatacept for Desensitization",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Highly Sensitized Prospective Kidney Transplant Recipients"
      ],
      "interventions": [
        {
          "name": "carfilzomib",
          "type": "BIOLOGICAL"
        },
        {
          "name": "belatacept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bone marrow aspiration",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 21,
      "start_date": "2021-12-28",
      "completion_date": "2028-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-10-27T05:20:59.362Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05017545"
    },
    {
      "nct_id": "NCT01959594",
      "title": "A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "3 mg PF-06412562",
          "type": "DRUG"
        },
        {
          "name": "10 mg PF-06412562",
          "type": "DRUG"
        },
        {
          "name": "25 mg PF-06412562",
          "type": "DRUG"
        },
        {
          "name": "PF-06412562 TBD mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 40,
      "start_date": "2013-11",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2014-03-28",
      "last_synced_at": "2026-10-27T05:20:59.362Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01959594"
    },
    {
      "nct_id": "NCT03742102",
      "title": "A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Triple Negative Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Capivasertib",
          "type": "DRUG"
        },
        {
          "name": "Oleclumab",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Datopotamab deruxtecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 130 Years · Female only"
      },
      "enrollment_count": 243,
      "start_date": "2018-12-21",
      "completion_date": "2027-02-26",
      "has_results": true,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-10-27T05:20:59.362Z",
      "location_count": 8,
      "location_summary": "Tucson, Arizona • Columbia, Maryland • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Columbia",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03742102"
    },
    {
      "nct_id": "NCT04418895",
      "title": "Neoadjuvant Therapy for Localized Rectal Adenocarcinoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rectal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Chemoradiation",
          "type": "OTHER"
        },
        {
          "name": "short course radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "mFOLFOX6",
          "type": "DRUG"
        },
        {
          "name": "CAPOX",
          "type": "DRUG"
        },
        {
          "name": "fluoropyrimidine +/- oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-08-13",
      "completion_date": "2025-05",
      "has_results": false,
      "last_update_posted_date": "2021-11-10",
      "last_synced_at": "2026-10-27T05:20:59.362Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04418895"
    }
  ]
}